Communiqués Curatis Holding AG

Actions

CURN

CH1330780979

Produits pharmaceutiques

Cours en clôture Swiss Exchange 18/09/2026			Varia. 5j.	Varia. 1 janv.
20,20 ^CHF	+6,88%		+6,88%	+68,33%

21/09	Bourse Zurich: le SMI rebondit, rassuré par la baisse du pétrole	AW
21/09	Bourse Zurich: début de semaine positif avec deux nouveaux au SMI	AW

Communiqués

21/09	Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)	BU
21/09	Strongest half-year in Curatis’s history — revenue up 51% and significant progress on corticorelin (C-PTBE-01)	EQ
11/06	Curatis Increases Revenue Growth Guidance for 2026	EQ
11/06	Curatis Increases Revenue Growth Guidance for 2026	BU
22/05	Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors	EQ
22/05	Curatis Holding AG announces CHF 3.0 million private placement with strategic investor	EQ
24/03	Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved	EQ
24/03	Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved	BU
11/03	Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in Japan	EQ
11/03	Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan	BU
25/11	Curatis : VALUATIONLAB	PU
21/11	Curatis Holding AG announces CHF 1.2 million private placement with strategic investor	EQ
18/09/25	FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3	EQ
18/09/25	Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3	BU
15/09/25	Curatis : Half Year Report 2025	PU
15/09/25	Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01	EQ
15/09/25	Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01	BU
05/09/25	Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues	EQ
05/09/25	Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues	BU
31/07/25	FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study	EQ
24/05/25	Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors	EQ
23/05/25	Curatis discloses Corticorelin as active substance of C-PTBE-01 \| Market Opportunity in PTBE expected to exceed USD 1 billion \| Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog	EQ
23/05/25	Curatis discloses Corticorelin as active substance of C-PTBE-01	BU
07/04/25	Curatis : VALUATIONLAB	PU
27/03/25	Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patientenzielgruppe beim Lead-Projekt C-PTBE-01	EQ